Business
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease and orphan-designated indicationClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other he
About this update from Longeveron Inc.
[{"type":"image","alt":"Longeveron","displaySize":"","headline":null,"caption":"Longeveron","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.X2J.blw.0f9XkdGnRbwAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a","width":300,"height":56},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/.X2J.blw.0f9XkdGnRbwAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a","width":300,"height":56}},"lazy":false},{"type":"text","content":"Stephen Willard","length":15,"tagName":"p"},{"type":"image","alt":"Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)","displaySize":"","headline":null,"caption":"Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":199,"height":279,"url":"https://media.zenfs.com/en/globenewswire.com/c984bd94a462025f570f855f240c80ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LP6Wln_Hwg53RYcHiDpu6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTUwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c984bd94a462025f570f855f240c80ff","width":199,"height":279},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/LP6Wln_Hwg53RYcHiDpu6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTUwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c984bd94a462025f570f855f240c80ff","width":199,"height":279}}},{"type":"list","items":[{"val":[{"type":"text","content":"On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease and orphan-designated indication","length":234,"tagName":"p"}]},{"val":[{"type":"text","content":"Closed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused funds","length":207,"tagName":"p"}]},{"val":[{"type":"text","content":"Company to host conference call and webcast today at 4:30 p.m. ET","length":65,"tag...